Upcoming catalyst for Zymeworks

Put ZYME on your radar - they’ve likely found an effective treatment for HER-2 positive breast and gastric cancer. I’ve watched this stock decline in price since late 2020 and believe it is undervalued. Current price targets are between 16-40.

Zymeworks will present on their clinical stage drug, zanidatamab, at the Oncology conference on June 3rd (double check - links below). It could be a nice momentum play or long term hold.

About In 2016, a family member was diagnosed with stage 4 gastric cancer at age 42. We watched her suffer through traditional chemo, lose her hair, etc only to have her cancer counts go back up. She started the clinical trial for zanidatamab in November 2019. She has technically been in full remission for the past 16 months. She has few, if any, side effects from the treatment. In fact, most damage to her thyroid and adrenal glands was done prior to joining the trial. What’s amazing is her cancer cells were adenocarcinoma. That’s the nasty cancer cell that hides very well and has evaded treatment until now.

We couldn’t be more thrilled with how she has done. Any other dd on company finances is welcome, but do know I anticipate great things from their trial results.






Appreciate you for making me aware of this one. Going to look at some calls a few months out.
Thank you for the “insider information” from your personal story. Glad to hear that person is doing so well.


This is quite interesting…

Background and potential reference prices / entries

ZYME was also subject to an offer at $10.50 from an investment fund as recently as end Apr which the board rejected at end May as they feel it undervalues the company’s long term prospects.

Open market purchases by the fund are a useful reference point as to where they see the floor price.

The also hold call options with a Dec expiry with strikes at $5 and $15

Lastly, another reference price point – company also did a share offering at $8 in Jan to raise capital

All in, entries around $6+ or 7 seem like decent entries, particularly if you believe in the strong prospects of its star drug, zanidatamab.

Clinical data / evaluation

However evaluating the drug’s prospects is where I struggle a little given all the technical terms, so would be useful if someone with a medical / biotech background could also weigh in…

Clinical trial data seems promising (based on my very limited understanding) and the share price has probably run up in response to presentations ZYME is making on Sat and Mon morning at the American Society of Clinical Oncology (ASCO) annual meeting. There will also be an investor call on Mon (6 Jun) at 4.30 ET which could be the catalyst for some price moves during Mon trading

Interesting thread comparing ZYME’s zanidatamab with a competing drug – Alphamab’s KN026, if you can understand the lingo :smiling_face_with_tear::

ZYME corporate presentation:


It looks like the July 10c have the most OI at 2k. Wonder if its multiple buyers vs one big buyer? Id rather buy farther out but the spread/OI gets significantly worse on other strikes and exp. Too bad it doesnt have weekly’s otherwise it might be worth trying to wheel. Might buy a few of the 10c Monday though.

Thanks for the DD mom!

ZYME board adopted a poison pill defence for the All Blue Falcons takeover bid

Under the Rights Plan, the rights will become exercisable if an entity, person or group acquires beneficial ownership of 10% or more of Zymeworks’ common shares, or 20% in the case of certain passive investors. In the event that the rights become exercisable due to the triggering ownership threshold being crossed, each right will entitle its holder (other than the person, entity or group triggering the Rights Plan, whose rights will become void and will not be exercisable) to purchase, at the then-current exercise price, additional shares of common stock having a then-current market value of twice the exercise price of the right.